Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) (the “Company”) and Palvella Therapeutics, Inc. Upon completion of the proposed transaction, Pieris shareholders are expected to own approximately 18% of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Pieris shareholders.